This strategy has the advantage of identifying a large number of patients with hidden diabetes, but the disadvantage is that the adopted diagnostic criteria will also include as diabetic patients a small number of patients who might have a prescription for antidiabetic drugs for an indication other than diabetes, for example, polycystic ovarian syndrome (metformin), obesity (metformin and incretin analogues), or gestational diabetes (metformin, insulin) [12]. The gene discussed is INS; the disease is Obesity.